Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Corrales, L."" wg kryterium: Autor


Wyświetlanie 1-5 z 5
Tytuł:
The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival.
Autorzy:
Turcott JG; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Martinez-Samano JE; Oncology Unit, Médica Sur, Mexico City, Mexico.
Cardona AF; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.; Oncology Unit, Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.; Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia.
Bassarmal SS; Oncology Unit, Clinica Alemana, Santiago, Chile.
Ramírez-Tirado LA; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Corrales L; Oncology Unit, Hospital San Juan de Dios, San José de Costa Rica, Costa Rica.
Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
Barragán-Castillo PA; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Ruiz-Patiño A; Oncology Unit, Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia.
Flores-Estrada D; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Pokaż więcej
Źródło:
Nutrition and cancer [Nutr Cancer] 2021; Vol. 73 (5), pp. 794-801. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/complications
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/complications
Lung Neoplasms*/therapy
Cachexia/etiology ; Humans ; Immunotherapy ; Weight Loss
Czasopismo naukowe
Tytuł:
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Autorzy:
Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
Corrales L; Medical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.; Thoracic Oncology Department, Centro de Investigación y Manejo del Cáncer - CIMCA, San José, Costa Rica.
Mas L; Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - IneN, Lima, Peru.
Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
Recondo G; Medical Oncology Department, Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina.
Ricaurte L; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
Rojas L; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Viola L; Thoracic Oncology Unit, Fundación Neumológica Colombiana- FNC, Bogotá, Colombia.
Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
Pino LE; Oncology Department, Institute of Oncology - ICAL, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Rolfo C; Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, USA.
Rosell R; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.
Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico.
Pokaż więcej
Corporate Authors:
CLICaP
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Sep; Vol. 11 (9), pp. 2552-2560. Date of Electronic Publication: 2020 Jul 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-Bacterial Agents/*adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Immunotherapy/*adverse effects
Lung Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Lung Neoplasms/pathology ; Male ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Autorzy:
Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.
Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
Raez LE; Thoracic Oncology Program, Memorial Cancer Institute/Florida International University, Miami, Florida, USA.
Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
Barrón F; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, Mexico.
Ricaurte L; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Bravo-Garzón MA; Hematology and Oncology Department, Hospital Militar Central, Bogotá, Colombia.
Mas L; Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - IneN, Lima, Peru.
Corrales L; Medical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.
Rojas L; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
Lupinacci L; Thoracic Oncology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Perazzo F; Section of Oncology, CEMIC Buenos Aires, Buenos Aires, Argentina.
Bas C; Oncology Department, Hospital Alemán, Buenos Aires, Argentina.
Carranza O; Oncology Department, Hospital Privado de la Comunidad de Mar del Plata, Mar del Plata, Argentina.
Puparelli C; Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos Aires, Argentina.
Rizzo M; Oncology Department, Hospital Austral de Buenos Aires, Buenos Aires, Argentina.
Ruiz R; Hematology and Oncology Department, Hospital Militar Central, Bogotá, Colombia.
Rolfo C; Thoracic Oncology Unit, Marlene and Stewart Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.
Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad el Bosque, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Pino LE; Oncology Department, Institute of Oncology - ICAL, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Ortíz C; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Laguado P; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Rosell R; Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.
Pokaż więcej
Corporate Authors:
CLICaP
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Feb; Vol. 11 (2), pp. 353-361. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*mortality
Carcinoma, Squamous Cell/*mortality
Immunotherapy/*mortality
Lung Neoplasms/*mortality
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Autorzy:
Cardona AF; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Rojas L; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.; Clinical Oncology Department, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia.
Wills B; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.
Carranza H; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Vargas C; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Otero J; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
Cuello M; Clinical Oncology Department, Hospital de Clínicas-UdeLAR, Montevideo, Uruguay.
Corrales L; Clinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.
Martín C; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.
Ortiz C; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Franco S; Clinical and Translational Oncology Group, Thoracic Oncology Unit, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
Rosell R; Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Pokaż więcej
Corporate Authors:
CLICaP
Źródło:
PloS one [PLoS One] 2016 May 18; Vol. 11 (5), pp. e0154293. Date of Electronic Publication: 2016 May 18 (Print Publication: 2016).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Thymidylate Synthase/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/administration & dosage ; Biopsy ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Combined Modality Therapy ; Female ; Humans ; Induction Chemotherapy ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Maintenance Chemotherapy ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Pemetrexed/administration & dosage ; Prognosis ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.
Autorzy:
Hsu YF; Division of Oncology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Ajona D
Corrales L
Lopez-Picazo JM
Gurpide A
Montuenga LM
Pio R
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2010 Jun 07; Vol. 9, pp. 139. Date of Electronic Publication: 2010 Jun 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Antineoplastic Agents/*pharmacology
Carcinoma, Non-Small-Cell Lung/*immunology
Complement Activation/*drug effects
Lung Neoplasms/*immunology
Animals ; Antibodies, Monoclonal, Humanized ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cell Line, Tumor ; Cetuximab ; ErbB Receptors/biosynthesis ; ErbB Receptors/genetics ; Female ; Fluorescent Antibody Technique ; Humans ; Lung Neoplasms/drug therapy ; Mice ; Mice, Nude ; Mutation ; Polymerase Chain Reaction ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins p21(ras) ; RNA, Messenger/analysis ; Xenograft Model Antitumor Assays ; ras Proteins/genetics
Czasopismo naukowe
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies